Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Small Lymphocytic Lymphoma
Related studies linked through entity extraction aliases.
A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
- Status
- COMPLETED
- Phase
- PHASE2
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
- Status
- COMPLETED
- Phase
- PHASE1
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)
- Status
- COMPLETED
- Phase
- PHASE1
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
- Status
- COMPLETED
- Phase
- PHASE2
Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
- Status
- COMPLETED
- Phase
- PHASE2
A Phase II Study of Doxycycline in Relapsed NHL
- Status
- TERMINATED
- Phase
- PHASE2
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07
- Status
- COMPLETED
- Phase
- PHASE3
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)
- Status
- TERMINATED
- Phase
- PHASE2
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
- Status
- COMPLETED
- Phase
- PHASE3
A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
- Status
- TERMINATED
- Phase
- NA
Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients
- Status
- UNKNOWN
- Phase
- N/A